Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics

Core Insights - TransMedics (TMDX) is expected to report quarterly earnings of $0.29 per share, reflecting a decline of 17.1% year over year, while revenues are forecasted to reach $123.56 million, an increase of 27.6% year over year [1] Group 1: Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1][2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [2] Group 2: Revenue Projections - Analysts project 'Net revenue by OCS product- OCS Lung net revenue' to be $5.19 million, indicating a decline of 8.4% year over year [4] - The consensus estimate for 'Net revenue by OCS product- OCS Liver net revenue' is $87.87 million, reflecting an increase of 31.3% from the previous year [4] - Estimated 'Net revenue by OCS product- OCS Heart net revenue' is $30.01 million, suggesting a year-over-year increase of 28.6% [4] Group 3: Geographic Revenue Estimates - Analysts expect 'Geographic Revenues- United States' to be $119.11 million, indicating a growth of 29.7% from the prior year [5] - The estimate for 'Geographic Revenues- All other countries' is projected at $4.09 million, reflecting a slight decline of 0.1% from the previous year [5] Group 4: Stock Performance - Shares of TransMedics have increased by 33% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.4% increase [6] - TransMedics holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [6]